VRTX Vertex Pharmaceuticals Incorporated - Common Stock

NASDAQ · Biotechnology · View on SEC EDGAR ↗

$436.65

Price · May 20, 2026

Fundamentals as of May 5, 2026

VRTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price

$436.65

Market Cap

$115.15B

P/E (TTM)

29.6

EPS (TTM)

$15.32

Revenue (TTM)

$12.00B

Div Yield

—

ROE

22.1%

Debt/Equity

—

52W Range

$363 – $508

VRTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $12.00B

2018-12-31 → 2025-12-31

EPS $15.32

2018-12-31 → 2025-12-31

Free Cash Flow $3.19B

2018-12-31 → 2025-12-31

Margins 32.9%

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric

5Y trend

VRTX

Peer Median

P/E (TTM)

29.6

18.2

P/S (TTM)

9.6

8.3

P/B

6.2

6.1

Price / FCF

36.1

—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric

5Y trend

VRTX

Peer Median

Operating Margin

34.8%

—

Net Profit Margin

32.9%

8.7%

ROA

16.4%

3.3%

ROE

22.1%

12.3%

ROIC

19.0%

—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric

5Y trend

VRTX

Peer Median

Current Ratio

2.9

3.6

Quick Ratio

2.2

—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric

5Y trend

VRTX

Peer Median

Revenue YoY

8.9%

—

Revenue CAGR 3Y

10.3%

—

Revenue CAGR 5Y

14.1%

—

EPS YoY

8.3%

—

Net Income YoY

9.0%

—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric

5Y trend

VRTX

Peer Median

EPS (Diluted)

$15.32

—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric

5Y trend

VRTX

Peer Median

VRTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 39 analysts

Strong Buy 13 33.3%
Buy 19 48.7%
Hold 6 15.4%
Sell 0 0.0%
Strong Sell 1 2.6%

12-Month Price Target

28 analysts · 2026-05-20

Median $556.50

Now $436.65

Low $330.00

High $641.00

Median target $556.50 +27.4%

Mean target $549.29 +25.8%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise

-0.02%

Period	EPS Actual	EPS Est	Surprise
March 31, 2026	$4.47	$4.40	0.07%
Dec. 31, 2025	$5.03	$5.17	-0.14%
Sept. 30, 2025	$4.80	$4.65	0.15%
June 30, 2025	$4.52	$4.37	0.15%
March 31, 2025	$4.06	$4.37	-0.31%

Peer Comparison Key metrics vs sector peers

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
VRTX	$115.15B	29.6	8.9%	32.9%	22.1%	—
ABBV	—	96.8	8.6%	6.9%	15367.3%	—
AMGN	$176.35B	23.0	10.0%	21.0%	95.9%	—
GILD	$152.32B	18.1	2.4%	28.9%	40.5%	—
REGN	$106.21B	18.6	0.99%	31.4%	14.7%	—
ALNY	$52.64B	170.7	65.2%	8.5%	60.4%	—
RVMD	—	—	—	—	—	—
NTRA	$32.00B	-150.7	35.9%	-9.0%	-14.1%	—

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 16

Annual Income Statement data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Revenue	$12.00B	$11.02B	$9.87B	$8.93B	$7.57B	$6.21B	$4.16B	$3.05B	·	$2.49B	$1.70B	$1.03B
Cost of Revenue	$1.65B	$1.53B	$1.26B	$1.08B	$904M	$736M	$548M	$410M	·	$275M	$210M	$117M
R&D Expense	·	·	·	·	$3.05B	$1.83B	$1.75B	$1.42B	·	$1.32B	$1.05B	$996M
SG&A Expense	$1.75B	$1.46B	$1.14B	$945M	$840M	$770M	$658M	$558M	·	$496M	$433M	$377M
Operating Expenses	$7.83B	$11.25B	$6.04B	$4.62B	$4.79B	$3.35B	$2.97B	$2.41B	·	$2.37B	$1.69B	$1.50B
Operating Income	$4.17B	$-233M	$3.83B	$4.31B	$2.78B	$2.86B	$1.20B	$635M	·	$123M	$10M	$-467M
Interest Expense	·	·	·	·	·	$58M	$59M	$72M	·	$69M	·	·
Other Non-op	$-8M	$-86M	$-23M	$-165M	$5M	$297M	$192M	$-790.0K	·	$-81M	$4M	$-7M
Pretax Income	$4.64B	$248M	$4.38B	$4.23B	$2.73B	$3.12B	$1.39B	$600M	·	$-16M	$-67M	$-558M
Income Tax	$690M	$784M	$760M	$910M	$388M	$405M	$218M	$-1.49B	·	$-107M	$17M	$30M
Net Income	$3.95B	$-536M	$3.62B	$3.32B	$2.34B	$2.71B	$1.18B	$2.10B	·	$263M	$-112M	$-556M
EPS (Basic)	$15.46	$-2.08	$14.05	$12.97	$9.09	$10.44	$4.58	$8.24	·	$1.06	$-0.46	$-2.31
EPS (Diluted)	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.29	$4.51	$8.09	·	$1.04	$-0.46	$-2.31
Shares (Basic)	255,700,000	257,900,000	257,700,000	256,100,000	257,700,000	259,800,000	256,700,000	254,292,000	·	248,858,000	244,685,000	241,312,000
Shares (Diluted)	258,000,000	257,900,000	260,500,000	259,100,000	259,900,000	263,400,000	260,700,000	259,185,000	·	253,225,000	244,685,000	241,312,000
EBITDA	$4.38B	$-26M	$4.01B	$4.46B	$2.91B	$2.97B	$1.30B	$708M	·	$185M	$71M	$-405M

Balance Sheet 27

Annual Balance Sheet data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Cash & Equivalents	$5.08B	$4.57B	$10.37B	$10.50B	$6.79B	$5.99B	$3.11B	$2.65B	·	$1.67B	$1.18B	$715M
Short-term Investments	$1.52B	$1.55B	$849M	$274M	$730M	$671M	$699M	$518M	·	$423M	$251M	$328M
Receivables	$2.05B	$1.61B	$1.56B	$1.44B	$1.14B	$885M	$634M	$410M	$311M	$281M	$200M	$174M
Inventory	$1.69B	$1.21B	$739M	$461M	$353M	$281M	$168M	$124M	$112M	$112M	$78M	$57M
Prepaid Expense	$853M	$666M	$624M	$554M	$546M	$308M	$214M	$141M	$150M	$167M	$71M	$55M
Other Current Assets	$111M	$76M	$84M	$74M	$59M	$80M	·	$62M	·	$76M	$34M	$13M
Current Assets	$11.20B	$9.60B	$14.14B	$13.23B	$9.56B	$8.13B	$4.82B	$3.84B	·	$2.65B	$1.83B	$1.41B
PP&E (Net)	·	·	·	·	·	·	$745M	$812M	·	$789M	$698M	$698M
PP&E (Gross)	·	·	·	·	·	·	·	$1.26B	·	$1.22B	$1.09B	$1.03B
Accum. Depreciation	·	·	·	·	·	·	·	$451M	·	$432M	$388M	$336M
Goodwill	$1.09B	$1.09B	$1.09B	$1.09B	$1.00B	$1.00B	$1.00B	$50M	·	$50M	$50M	$50M
Intangibles	$424M	$826M	$840M	$604M	$400M	$400M	$400M	$0	·	·	·	·
Other Non-current Assets	$1.24B	$999M	$895M	$410M	$111M	$49M	$69M	$41M	·	$27M	$12M	$7M
Total Assets	$25.64B	$22.53B	$22.73B	$18.15B	$13.43B	$11.75B	$8.32B	$6.25B	$3.56B	$3.55B	$2.90B	$2.50B
Accounts Payable	$462M	$413M	$365M	$304M	$195M	$155M	$88M	$111M	·	$74M	$61M	$75M
Accrued Liabilities	$2.97B	$2.79B	$2.66B	$2.13B	$1.68B	$1.41B	$1.12B	$959M	$453M	$444M	$315M	$306M
Current Liabilities	$3.86B	$3.56B	$3.55B	$2.74B	$2.14B	$1.88B	$1.33B	$1.12B	·	$807M	$793M	$506M
Capital Leases	$1.85B	$1.54B	$349M	$380M	$377M	$350M	$84M	$20M	·	$20M	$35M	$43M
Deferred Tax	·	·	·	·	·	·	·	$0	·	$6M	$134M	$110M
Other Non-current Liabilities	$1.27B	$1.01B	$878M	$686M	$303M	$108M	$99M	$109M	·	$28M	$29M	$32M
Total Liabilities	$6.98B	$6.12B	$5.15B	$4.24B	$3.33B	$3.06B	$2.23B	$1.81B	·	$1.50B	$1.56B	$1.40B
Common Stock	$2M	$3M	$3M	$3M	$2M	$3M	$3M	$3M	·	$3M	$2M	$2M
Retained Earnings	$13.56B	$9.61B	$10.14B	$6.52B	$3.20B	$859M	$-1.85B	$-2.99B	$-5.11B	$-5.12B	$-5.37B	$-5.26B
AOCI	$-16M	$128M	$-14M	$800.0K	$16M	$-68M	$-2M	$659.0K	$-11M	$-12M	$21M	$2M
Stockholders' Equity	$18.67B	$16.41B	$17.58B	$13.91B	$10.10B	$8.69B	$6.09B	$4.44B	·	$2.04B	$1.34B	$940M
Liabilities + Equity	$25.64B	$22.53B	$22.73B	$18.15B	$13.43B	$11.75B	$8.32B	$6.25B	$3.56B	$3.55B	$2.90B	$2.50B
Shares Outstanding	253,991,224	256,900,000	257,700,000	257,000,000	254,500,000	259,900,000	259,000,000	255,172,000	·	253,253,362	248,300,517	246,306,818

Cash Flow 16

Annual Cash Flow data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
D&A	$210M	$207M	$181M	$148M	$126M	$110M	$107M	$72M	·	$61M	$61M	$62M
Stock-based Comp	$686M	$698M	$581M	$491M	$441M	$430M	$360M	$325M	·	$293M	$241M	$231M
Deferred Tax	$-511M	$-349M	$-536M	$-276M	$-155M	$277M	$167M	$-1.51B	·	$-127M	$17M	$298.0K
Amort. of Intangibles	$20M	$20M	$2M	·	·	·	·	·	·	·	·	·
Restructuring	·	·	·	·	·	$0	$0	$-184.0K	·	$14M	$1M	$2M
Other Non-cash	$-707M	$-514M	$-308M	$444M	$-111M	$-274M	$-242M	$288M	·	$357M	$32M	$-103M
Operating Cash Flow	$3.63B	$-493M	$3.54B	$4.13B	$2.64B	$3.25B	$1.57B	$1.27B	·	$845M	$236M	$-365M
CapEx	$438M	$298M	$200M	$205M	$235M	$260M	$75M	$95M	·	$99M	$57M	$45M
Investing Cash Flow	$-945M	$-3.77B	$-3.14B	$-321M	$-341M	$99M	$-1.24B	$-202M	·	$-483M	$51M	$269M
Stock Repurchased	$2.02B	$1.18B	$428M	$0	$1.43B	$539M	$186M	$350M	·	$0	$0	·
Net Stock Activity	$-2.02B	$-1.18B	$-428M	$0	$-1.43B	$-539M	$-192M	$-350M	·	·	·	·
Financing Cash Flow	$-2.26B	$-1.49B	$-562M	$-68M	$-1.48B	$-505M	$127M	$-71M	·	$68M	$133M	$189M
Net Change in Cash	$516M	$-5.80B	$-140M	$3.71B	$811M	$2.87B	$462M	$991M	·	$436M	$416M	$90M
Taxes Paid	$1.57B	$1.08B	$1.68B	$1.06B	$476M	$192M	$25M	$12M	·	$6M	$-3M	$2M
Free Cash Flow	$3.19B	$-790M	$3.34B	$3.93B	$2.41B	$2.99B	$1.49B	$1.17B	·	$746M	$180M	$-411M
Levered FCF	·	·	·	·	·	$2.94B	$1.44B	·	·	·	·	·

Profitability 7

Annual Profitability data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Operating Margin	34.8%	-2.1%	38.8%	48.2%	36.7%	46.0%	28.8%	20.8%	·	5.0%	0.58%	-45.2%
Net Margin	32.9%	-4.9%	36.7%	37.2%	30.9%	43.7%	28.3%	68.8%	·	10.6%	-6.6%	-53.9%
Pretax Margin	38.7%	2.2%	44.4%	47.4%	36.0%	50.2%	33.5%	19.7%	·	-0.63%	-4.0%	-54.0%
EBITDA Margin	36.5%	-0.23%	40.7%	49.9%	38.4%	47.8%	31.3%	23.2%	·	7.4%	4.2%	-39.2%
ROA	16.4%	-2.4%	17.7%	21.0%	18.6%	27.0%	16.1%	42.8%	·	8.2%	-4.2%	-23.0%
ROE	22.1%	-3.3%	21.2%	24.7%	23.9%	32.2%	20.8%	56.9%	·	15.7%	-10.7%	-55.2%
ROIC	19.0%	3.1%	18.0%	24.3%	23.6%	28.6%	16.6%	49.8%	·	-35.5%	1.1%	-52.4%

Liquidity & Solvency 3

Annual Liquidity & Solvency data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Current Ratio	2.9	2.7	4.0	4.8	4.5	4.3	3.6	3.4	·	3.3	2.3	2.8
Quick Ratio	2.2	2.2	3.6	4.5	4.0	4.0	3.3	3.2	·	2.9	2.1	2.4
Interest Coverage	·	·	·	·	·	49.1	20.5	·	·	·	·	·

Efficiency 3

Annual Efficiency data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Asset Turnover	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	·	0.8	0.6	0.4
Inventory Turnover	1.1	1.6	2.1	2.7	2.9	3.3	3.8	3.5	·	2.9	3.1	2.7
Receivables Turnover	6.6	6.9	6.6	6.9	7.5	8.2	8.0	8.5	·	10.3	9.1	8.1

Per Share 5

Annual Per Share data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Book Value / Share	$73.49	$63.87	$68.22	$54.13	$39.69	$33.42	$23.50	$17.38	·	$8.01	$4.66	$3.82
Revenue / Share	$46.52	$42.73	$37.89	$34.47	$29.14	$23.56	$15.97	$11.76	·	$9.83	$6.96	$4.28
Cash Flow / Share	$14.08	$-1.91	$13.58	$15.94	$10.17	$12.35	$6.02	$4.90	·	$3.34	$0.96	$-1.51
Cash / Share	$20.02	$17.78	$40.24	$40.87	$26.70	$23.04	$12.01	$10.39	·	$6.58	$4.77	$2.90
EPS (TTM)	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.29	$4.51	$8.09	·	$1.04	$-0.46	$-2.31

Growth Rates 9

Annual Growth Rates data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Revenue YoY	8.9%	11.7%	10.5%	17.9%	22.1%	·	·	·	·	·	·	·
Revenue CAGR 3Y	10.3%	13.3%	16.7%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	14.1%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	·	·	8.3%	42.3%	-12.4%	·	·	·	·	·	·	·
EPS CAGR 3Y	6.1%	·	10.5%	·	·	·	·	·	·	·	·	·
EPS CAGR 5Y	8.3%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	·	·	9.0%	41.8%	-13.6%	·	·	·	·	·	·	·
Net Income CAGR 3Y	6.0%	·	10.1%	·	·	·	·	·	·	·	·	·
Net Income CAGR 5Y	7.8%	·	·	·	·	·	·	·	·	·	·	·

Valuation (TTM) 10

Annual Valuation (TTM) data for VRTX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2018	2017	2016	2015
Revenue TTM	$12.00B	$11.02B	$9.87B	$8.93B	$7.57B	$6.21B	$4.16B	$3.05B	·	$2.49B	$1.70B	$1.03B
Net Income TTM	$3.95B	$-536M	$3.62B	$3.32B	$2.34B	$2.71B	$1.18B	$2.10B	·	$263M	$-112M	$-556M
Market Cap	$115.15B	$103.47B	$104.85B	$74.22B	$55.88B	$61.42B	$56.71B	$42.28B	·	$37.95B	$18.29B	$30.99B
P/E	29.6	-193.6	29.3	22.5	24.4	23.0	48.5	20.5	·	144.1	-160.2	-54.5
P/S	9.6	9.4	10.6	8.3	7.4	9.9	13.6	13.9	·	15.3	10.7	30.0
P/B	6.2	6.3	6.0	5.3	5.5	7.1	9.3	9.5	·	18.7	15.8	33.0
P / Tangible Book	6.7	7.1	6.7	6.1	6.4	8.4	·	·	·	·	·	·
P / Cash Flow	31.7	-210.0	29.6	18.0	21.1	18.9	36.1	33.3	·	44.9	77.5	-84.8
P / FCF	36.1	-130.9	31.4	18.9	23.2	20.5	38.0	36.0	·	50.9	101.9	-75.5
Earnings Yield	3.4%	-0.52%	3.4%	4.4%	4.1%	4.3%	2.1%	4.9%	·	0.69%	-0.62%	-1.8%

Income Statement 14

Quarterly Income Statement data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Revenue	$2.99B	$3.19B	$3.08B	$2.96B	$2.77B	$2.91B	$2.77B	$2.65B	$2.69B	$2.52B	$2.48B	$2.49B	$2.37B	$2.30B	$2.33B	$2.20B
Cost of Revenue	$393M	$466M	$415M	$408M	$363M	$423M	$393M	$372M	$343M	$368M	$319M	$309M	$267M	$283M	$289M	$262M
SG&A Expense	$494M	$487M	$445M	$425M	$396M	$378M	$372M	$372M	$343M	$369M	$264M	$263M	$241M	$267M	$247M	$215M
Operating Expenses	$1.85B	$1.98B	$1.89B	$1.81B	$2.14B	$1.89B	$1.66B	$6.16B	$1.55B	$1.53B	$1.45B	$1.47B	$1.60B	$1.27B	$1.21B	$1.09B
Operating Income	$1.14B	$1.21B	$1.19B	$1.15B	$630M	$1.03B	$1.12B	$-3.51B	$1.14B	$988M	$1.04B	$1.03B	$779M	$1.03B	$1.13B	$1.11B
Other Non-op	$0	$6M	$-10M	$13M	$-18M	$-15M	$-17M	$-23M	$-31M	$-10M	$-16M	$2M	$1M	$-31M	$17M	$-78M
Pretax Income	$1.25B	$1.33B	$1.30B	$1.28B	$730M	$1.14B	$1.22B	$-3.39B	$1.28B	$1.15B	$1.18B	$1.16B	$892M	$1.08B	$1.18B	$1.02B
Income Tax	$222M	$140M	$216M	$250M	$84M	$224M	$179M	$202M	$180M	$179M	$144M	$246M	$192M	$258M	$246M	$214M
Net Income	$1.03B	$1.19B	$1.08B	$1.03B	$646M	$913M	$1.05B	$-3.59B	$1.10B	$969M	$1.04B	$916M	$700M	$819M	$930M	$810M
EPS (Basic)	$4.06	$4.68	$4.24	$4.02	$2.52	$3.53	$4.05	$-13.92	$4.26	$3.77	$4.01	$3.55	$2.72	$3.18	$3.63	$3.17
EPS (Diluted)	$4.02	$4.64	$4.20	$3.99	$2.49	$3.62	$4.01	$-13.92	$4.21	$3.71	$3.97	$3.52	$2.69	$3.14	$3.59	$3.13
Shares (Basic)	254,100,000	-513,500,000	255,600,000	256,700,000	256,900,000	-516,400,000	258,000,000	258,100,000	258,200,000	-515,400,000	258,000,000	257,700,000	257,400,000	-511,400,000	256,500,000	255,900,000
Shares (Diluted)	256,300,000	-518,000,000	257,600,000	258,900,000	259,500,000	-522,300,000	261,000,000	258,100,000	261,100,000	-520,800,000	260,600,000	260,400,000	260,300,000	-517,000,000	259,500,000	258,700,000
EBITDA	$1.19B	·	$1.24B	$1.20B	$678M	·	$1.12B	$-3.51B	$1.19B	·	$1.04B	$1.03B	$818M	·	$1.13B	$1.11B

Balance Sheet 23

Quarterly Balance Sheet data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Cash & Equivalents	$5.49B	$5.08B	$4.94B	$4.97B	$4.67B	$4.57B	$5.24B	$4.58B	$9.16B	$10.37B	$11.11B	$10.15B	$9.29B	$10.50B	$9.17B	$8.70B
Short-term Investments	$1.75B	$1.52B	$1.35B	$1.41B	$1.53B	$1.55B	$1.29B	$1.22B	$1.01B	·	$818M	$1.09B	$1.12B	·	$599M	$551M
Receivables	$2.00B	$2.05B	$1.95B	$1.89B	$1.81B	$1.61B	$1.75B	$1.66B	$1.79B	·	$1.54B	$1.56B	$1.55B	·	$1.39B	$1.33B
Inventory	$1.77B	$1.69B	$1.63B	$1.50B	$1.36B	$1.21B	$1.08B	$915M	$813M	·	$689M	$604M	$535M	·	$388M	$368M
Prepaid Expense	$721M	$853M	$709M	$652M	$643M	$666M	$449M	$575M	$511M	·	$540M	$477M	$469M	·	$727M	$550M
Other Current Assets	·	$111M	·	·	·	$76M	·	·	·	·	·	·	·	·	·	·
Current Assets	$11.73B	$11.20B	$10.57B	$10.43B	$10.01B	$9.60B	$9.80B	$8.94B	$13.29B	·	$14.70B	$13.87B	$12.97B	·	$12.27B	$11.50B
Goodwill	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	·	$1.09B	$1.09B	$1.09B	·	$1.08B	$1.00B
Intangibles	$418M	$424M	$430M	$436M	$441M	$826M	$832M	$838M	$835M	·	$604M	$604M	$604M	·	$604M	$387M
Other Non-current Assets	$1.26B	$1.24B	$1.10B	$1.08B	$1.01B	$999M	$990M	$916M	$876M	·	$475M	$443M	$428M	·	$132M	$127M
Total Assets	$26.48B	$25.64B	$24.86B	$24.04B	$22.88B	$22.53B	$22.24B	$20.13B	$23.92B	·	$21.73B	$20.35B	$18.97B	·	$16.71B	$15.58B
Accounts Payable	$489M	$462M	$420M	$442M	$445M	$413M	$396M	$328M	$351M	·	$376M	$363M	$323M	·	$127M	$198M
Accrued Liabilities	$2.98B	$2.97B	$3.61B	$3.27B	$2.95B	$2.79B	$3.22B	$2.94B	$2.80B	·	$2.91B	$2.60B	$2.33B	·	$2.26B	$2.12B
Current Liabilities	$3.88B	$3.86B	$4.48B	$4.14B	$3.78B	$3.56B	$3.97B	$3.55B	$3.80B	·	$3.60B	$3.35B	$3.03B	·	$2.61B	$2.56B
Capital Leases	$1.99B	$1.85B	$1.83B	$1.53B	$1.54B	$1.54B	$1.59B	$587M	$360M	·	$354M	$364M	$372M	·	$382M	$365M
Other Non-current Liabilities	$1.26B	$1.27B	$1.23B	$1.20B	$952M	$1.01B	$933M	$877M	$854M	·	$869M	$759M	$726M	·	$116M	$115M
Total Liabilities	$7.12B	$6.98B	$7.54B	$6.86B	$6.38B	$6.12B	$6.61B	$5.36B	$5.37B	·	$5.21B	$4.88B	$4.54B	·	$3.68B	$3.65B
Common Stock	$2M	$2M	$2M	$3M	$3M	$3M	$3M	$3M	$3M	·	$3M	$3M	$3M	·	$3M	$3M
Retained Earnings	$14.59B	$13.56B	$12.37B	$11.29B	$10.25B	$9.61B	$8.69B	$7.65B	$11.24B	·	$9.17B	$8.14B	$7.22B	·	$5.70B	$4.77B
AOCI	$25M	$-16M	$-64M	$-101M	$68M	$128M	$29M	$22M	$17M	·	$-3M	$-40M	$-13M	·	$98M	$58M
Stockholders' Equity	$19.36B	$18.67B	$17.32B	$17.18B	$16.50B	$16.41B	$15.63B	$14.77B	$18.55B	$17.58B	$16.51B	$15.47B	$14.43B	$13.91B	$13.03B	$11.93B
Liabilities + Equity	$26.48B	$25.64B	$24.86B	$24.04B	$22.88B	$22.53B	$22.24B	$20.13B	$23.92B	·	$21.73B	$20.35B	$18.97B	·	$16.71B	$15.58B
Shares Outstanding	254,163,953	253,991,224	253,951,475	256,293,058	256,967,767	256,940,382	257,739,599	258,015,301	258,296,249	257,700,000	257,828,508	257,792,648	257,509,761	257,000,000	256,645,737	256,026,201

Cash Flow 12

Quarterly Cash Flow data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
D&A	$56M	$56M	$54M	$52M	$48M	$46M	$53M	$54M	$54M	$59M	$42M	$41M	$39M	$38M	$37M	$37M
Stock-based Comp	$166M	$158M	$195M	$167M	$166M	$168M	$185M	$154M	$192M	$209M	$131M	$119M	$122M	$112M	$136M	$114M
Other Non-cash	$174M	·	·	·	$-42M	·	·	·	$-38M	·	·	·	$39M	·	·	·
Operating Cash Flow	$1.43B	$498M	$1.24B	$1.07B	$819M	$585M	$1.37B	$-3.75B	$1.31B	$235M	$1.27B	$1.13B	$900M	$1.08B	$956M	$1.14B
CapEx	$133M	$149M	$102M	$146M	$41M	$93M	$68M	$69M	$68M	$58M	$41M	$60M	$42M	$34M	$54M	$53M
Investing Cash Flow	$-432M	$-288M	$-117M	$-484M	$-56M	$-822M	$-348M	$-464M	$-2.14B	$-886M	$-118M	$-304M	$-1.83B	$176M	$-384M	$-62M
Stock Repurchased	$337M	$128M	$1.07B	$392M	$426M	$418M	$308M	$320M	$131M	$150M	$117M	$28M	$133M	$0	$0	$0
Net Stock Activity	$-337M	·	·	·	$-426M	·	·	·	$-131M	·	·	·	$-133M	·	·	·
Financing Cash Flow	$-539M	$-77M	$-1.15B	$-349M	$-680M	$-391M	$-388M	$-359M	$-358M	$-120M	$-165M	$17M	$-295M	$40M	$-60M	$48M
Net Change in Cash	$417M	$140M	$-34M	$297M	$113M	$-676M	$657M	$-4.58B	$-1.20B	$-744M	$963M	$858M	$-1.22B	$1.33B	$473M	$1.10B
Taxes Paid	$82M	$389M	$480M	$513M	$184M	$272M	$278M	$497M	$35M	$758M	$300M	$498M	$120M	$218M	$362M	$393M
Free Cash Flow	$1.29B	·	·	·	$778M	·	·	·	$1.24B	·	·	·	$858M	·	·	·

Profitability 7

Quarterly Profitability data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Operating Margin	38.1%	·	38.6%	38.8%	22.8%	·	40.3%	-132.8%	42.4%	·	41.8%	41.2%	32.8%	·	48.3%	50.4%
Net Margin	34.5%	·	35.2%	34.8%	23.3%	·	37.7%	-135.8%	40.9%	·	41.7%	36.7%	29.5%	·	39.9%	36.9%
Pretax Margin	41.9%	·	42.2%	43.3%	26.4%	·	44.2%	-128.2%	47.5%	·	47.5%	46.6%	37.5%	·	50.4%	46.6%
EBITDA Margin	40.0%	·	40.3%	40.6%	24.5%	·	40.3%	-132.8%	44.3%	·	41.8%	41.2%	34.4%	·	48.3%	50.4%
ROA	4.2%	·	4.6%	4.7%	2.8%	·	4.8%	-17.8%	5.1%	·	5.4%	5.1%	4.2%	·	6.3%	5.8%
ROE	5.8%	·	6.6%	6.5%	3.7%	·	6.5%	-23.8%	6.7%	·	7.0%	6.7%	5.5%	·	8.2%	7.7%
ROIC	4.8%	·	5.7%	5.4%	3.4%	·	6.1%	-25.2%	5.3%	·	5.5%	5.2%	4.2%	·	6.8%	7.3%

Liquidity & Solvency 2

Quarterly Liquidity & Solvency data for VRTX
Metric	Trend	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Current Ratio		3.0	·	2.4	2.5	2.6	·	2.5	2.5	3.5	·	4.1	4.1	4.3	·	4.7	4.5
Quick Ratio		2.4	·	1.8	2.0	2.1	·	2.1	2.1	3.2	·	3.7	3.8	4.0	·	4.3	4.1

Efficiency 3

Quarterly Efficiency data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Asset Turnover	0.1	·	0.1	0.1	0.1	·	0.1	0.1	0.1	·	0.1	0.1	0.1	·	0.2	0.2
Inventory Turnover	0.3	·	0.3	0.3	0.3	·	0.4	0.5	0.5	·	0.6	0.6	0.6	·	0.8	0.8
Receivables Turnover	1.6	·	1.7	1.7	1.5	·	1.7	1.6	1.6	·	1.7	1.7	1.7	·	1.9	1.9

Per Share 5

Quarterly Per Share data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Book Value / Share	$76.18	·	$68.20	$67.01	$64.20	·	$60.65	$57.26	$71.80	·	$64.05	$60.01	$56.05	·	$50.77	$46.61
Revenue / Share	$11.65	·	$11.94	$11.45	$10.68	·	$10.62	$10.25	$10.30	·	$9.53	$9.57	$9.12	·	$9.00	$8.49
Cash Flow / Share	$5.57	·	·	·	$3.16	·	·	·	$5.00	·	·	·	$3.46	·	·	·
Cash / Share	$21.61	·	$19.45	$19.40	$18.19	·	$20.33	$17.75	$35.46	·	$43.09	$39.38	$36.08	·	$35.74	$33.99
EPS (TTM)	$14.70	·	$14.69	$-3.43	$-3.21	·	$-1.73	$-2.22	$14.39	·	$13.77	$12.93	$12.37	·	$12.96	$9.63

Valuation (TTM) 10

Quarterly Valuation (TTM) data for VRTX
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Revenue TTM	$11.80B	·	$11.58B	$11.15B	$10.88B	·	$10.59B	$10.31B	$10.04B	·	$9.69B	$9.40B	$9.00B	·	$8.61B	$8.07B
Net Income TTM	$3.79B	·	$3.81B	$-869M	$-802M	·	$-413M	$-543M	$3.75B	·	$3.58B	$3.36B	$3.20B	·	$3.35B	$2.49B
Market Cap	$113.49B	·	$99.46B	$114.10B	$124.58B	·	$119.87B	$120.94B	$107.97B	·	$89.66B	$90.72B	$81.13B	·	$74.31B	$72.15B
P/E	30.4	·	26.7	-129.8	-151.0	·	-268.8	-211.1	29.0	·	25.3	27.2	25.5	·	22.3	29.3
P/S	9.6	·	8.6	10.2	11.5	·	11.3	11.7	10.8	·	9.3	9.7	9.0	·	8.6	8.9
P/B	5.9	·	5.7	6.6	7.6	·	7.7	8.2	5.8	·	5.4	5.9	5.6	·	5.7	6.0
P / Tangible Book	6.4	·	6.3	7.3	8.3	·	8.7	9.4	6.5	·	6.0	6.6	6.4	·	6.5	6.8
P / Cash Flow	79.5	·	·	·	152.1	·	·	·	82.6	·	·	·	90.2	·	·	·
P / FCF	87.7	·	·	·	160.1	·	·	·	87.2	·	·	·	94.6	·	·	·
Earnings Yield	3.3%	·	3.8%	-0.77%	-0.66%	·	-0.37%	-0.47%	3.4%	·	4.0%	3.7%	3.9%	·	4.5%	3.4%

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$12.00B	$11.02B	$9.87B	$8.93B	$7.57B
Operating Margin %	34.8%	-2.1%	38.8%	48.2%	36.7%
Net Income	$3.95B	$-536M	$3.62B	$3.32B	$2.34B
Diluted EPS	$15.32	$-2.08	$13.89	$12.82	$9.01

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	2.9	2.7	4.0	4.8	4.5
Quick Ratio	2.2	2.2	3.6	4.5	4.0

Cash Flow

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$3.19B	$-790M	$3.34B	$3.93B	$2.41B

VRTX AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.65

↑ Bullish

I see Vertex's bull case hinging on its fortress-like profitability from cystic fibrosis dominance, fueling R&D without debt drag as new therapies like pain drugs gain traction. Gross margin holds at 86%, proving they command premium pricing peers can't match in specialty pharma. Net margin sits at 31%, generating ample cash to fund the pipeline Morgan Stanley just pegged with a $612 target—30% above today's $469 close. Zero debt-to-equity means no interest burden, pure resilience in biotech volatility.

↓ Bearish

My strongest bear case is Vertex's stagnant earnings growth trapping it at a premium valuation that crumbles if pipeline bets falter amid patent cliffs. EPS TTM flat at $14.23 offers no acceleration to justify the ride. ROE of 21.8% lags peers like AMGN's 96%, signaling weaker capital efficiency despite the hype. P/E at 31 tops GILD's 19, baking in perfection with recent May plunge from $501 to $425 exposing sentiment fragility.

Claude NEUTRAL 0.68

↑ Bullish

Vertex is a rare pharma compounder with pricing power and fortress balance sheet. The 86% gross margin and 31% net margin tell you this is a franchise business, not a commodity play — drugs that patients need and doctors prescribe. Zero debt and a 2.36x current ratio mean management can fund R&D or M&A without dilution. Morgan Stanley's $612 target (April 2026) implies 30% upside from current levels, and that call comes after the stock already ran from $424 in May to $469 today. The market is rewarding execution, not pricing in speculation.

↓ Bearish

The valuation has already priced in years of flawless execution. At 31.3x trailing earnings and 9.8x sales, Vertex trades at a 25% premium to Amgen and a 67% premium to Gilead despite slower ROE growth. The stock has been volatile — down 15% in one week (May 9 close $425 to May 16 open $425, then recovery), signaling institutional uncertainty about pipeline or competitive threats. If a single late-stage trial fails or a competitor launches a better-in-class drug, the multiple compresses fast. Biotech multiples are mean-reverting, and this one is stretched.

Gemini NEUTRAL 0.75

↑ Bullish

Vertex is effectively a fortress of profitability that has successfully eliminated its balance sheet risk. The company currently carries a Debt/Equity ratio of 0.0, which means they are operating entirely on their own cash flow rather than relying on creditors. This financial independence is bolstered by a massive 86.28% gross margin. This indicates that for every dollar of medicine they sell, they keep over 86 cents before operating costs, showcasing incredible pricing power in the specialty pharma space.

↓ Bearish

The market has already priced in a premium for Vertex's stability, leaving little room for error if growth slows. Investors are currently paying a P/E ratio of 31.29. This means you are paying over 31 dollars for every dollar of annual earnings, which is significantly higher than peers like Gilead. Furthermore, at a P/S ratio of 9.81, the stock is trading at a high multiple relative to its actual sales. This suggests the market is betting on aggressive future expansion that the current financials may struggle to justify.

Chatgpt NEUTRAL 0.65

↑ Bullish

I think Vertex's strongest bullish case is that it combines standout profitability with a debt-free balance sheet, creating room to fund a robust pipeline. ROE TTM 21.81%. That means Vertex converts equity into profit at about 22 cents on the dollar, signaling efficient capital use. Gross margin TTM 86.28%. That cushion shows pricing power and scalable operations, giving Vertex resilience if costs rise. Debt/equity 0.0. With no net debt, the company has optionality to fund late-stage trials or weather downturns. If the pipeline delivers, this setup could compound earnings and cash flow into 2026Q2.

↓ Bearish

I think Vertex's valuation is the main headwind; the stock is priced for perfection, leaving little cushion for any hiccup in the pipeline. P/E TTM 31.30. That premium implies the market expects sustained growth; any slowdown can trigger multiple compression. P/S TTM 9.81. A high sales multiple means investors rely on rapid revenue gains; if growth slows, the multiple contracts. AMGN P/E 25.16. Vertex trades well above this peer, which raises downside risk if catalysts lag.

Round 2 — Responses & Rebuttals

Grok

ChatGPT, Vertex's 21.8% ROE isn't an efficiency standout as you portray it because it lags peers like Amgen's 96.2%, showing Vertex turns far less equity into profit despite zero debt removing any leverage excuse. That peer gap underscores why the 31x P/E demands faster earnings growth to hold up into 2026Q2—stagnant EPS at $14.23 leaves no margin for error if pipeline delays hit.

Claude

I need to push back on ChatGPT's ROE math here. ChatGPT said a 21.81% ROE means Vertex converts equity into profit at 'about 22 cents on the dollar'—that's backwards. ROE of 21.81% means for every dollar of shareholder equity on the balance sheet, Vertex generates 21.8 cents of annual profit. That's actually strong for pharma, not weak. The real issue ChatGPT missed is that Vertex's ROE is half of Amgen's 96%, which Grok flagged correctly. If Vertex is deploying capital half as efficiently as its peer despite the fortress balance sheet and premium margins, that's the real efficiency question—not whether 22% ROE is acceptable in isolation. The valuation premium only holds if Vertex can close that gap.

Gemini

Grok, your point about the ROE comparison to Amgen is misleading because you are ignoring the massive difference in capital structure. Amgen’s 96% ROE is heavily inflated by high leverage, whereas Vertex’s 21.81% ROE is generated with zero debt. That metric means Vertex is creating significant shareholder value using only its own operational cash rather than borrowed money. While I agree the valuation is stretched, comparing a debt-free company to a highly leveraged peer makes the capital efficiency look worse than it actually is for the business.

Chatgpt

Claude, your point about Vertex's fortress balance sheet is strong, but the stock's valuation still matters. P/E TTM is 31.3, which means investors are paying a premium for durable earnings rather than cheap growth. That premium leaves less room for error if the pipeline slows or a competitor gains traction, since the multiple can compress quickly in biotech when sentiment shifts.

Round 3 — Final Rebuttals

Grok

Gemini, your leverage defense of Vertex's ROE doesn't fully hold because the company's own deleveraging proves operations aren't closing the peer gap. Debt/equity stood at 0.68 in 2025Q3. That modest leverage generated 22.14% ROE, turning each equity dollar into solid but unexceptional profit. Now debt-free, ROE is 21.81%. No efficiency gain emerged without the debt tailwind—still half Amgen's output, so the comparison stands and pressures the 31x P/E for pipeline proof.

Claude

I want to push back on something nobody has touched yet: Vertex's revenue concentration risk. Cystic fibrosis drugs—Kalydeco, Orkambi, Trikafta—likely represent 70% or more of total revenue, and that franchise is mature. The company is betting pipeline expansion into pain, obesity, and other indications will offset CF plateau, but we haven't seen material revenue traction from those programs yet. Morgan Stanley's $612 target assumes successful launches, but if those trials slip or underperform, Vertex faces a revenue cliff that no amount of margin strength absorbs. That's the real tail risk hiding behind the 31x multiple—not just multiple compression, but actual earnings compression if the new drugs don't land. Gemini and Grok, how much of that $612 target depends on pipeline success versus CF maintenance?

Gemini

Grok, I have to challenge your assertion that Vertex’s stagnant EPS at $14.23 is the primary risk, because it ignores the massive, upcoming shift in their revenue mix. Vertex is currently transitioning from a cystic fibrosis monopoly to a broader specialty platform, specifically with the launch of their non-opioid pain treatment, suzetrigine. This drug targets a massive, underserved market that could fundamentally alter their growth trajectory by 2026Q2. While the current P/E of 31.3 is high, that multiple represents the market betting on this pipeline expansion, not just the current, stable earnings base.

Chatgpt

I’m widening the frame, Claude, Grok, Gemini, to factor policy and competitive dynamics into Vertex’s price action. P/E TTM around 31x. That premium implies investors expect durable earnings, but it can compress if policy shifts like CMS price negotiations bite Vertex's US pricing and if a late-stage competitor data readout in 2026 confirms stronger pipeline risk, potentially capping upside into 2026Q2.

Price Forecasts

Model	3M Target	6M Target	Reasoning
G Grok	3M Target $510.00	6M Target $540.00	Reasoning I think Vertex consolidates upward modestly from $494 as CF franchise cash flows defend the premium valuation into 2026Q2, but lacks acceleration without pipeline wins. The key catalyst is suzetrigine Phase 3 topline data expected by Q4 2025, which could unlock non-opioid pain revenue and bridge stagnant EPS growth. The main risk is a trial miss exposing CF concentration, compressing multiples fast. Holding 31x P/E at my 6-month $540 target means the market still demands proof of 15%+ earnings expansion to sustain the peer premium over GILD's 19x.
C Claude	3M Target $485.00	6M Target $520.00	Reasoning Vertex's bull case hinges on pipeline expansion offsetting cystic fibrosis plateau—but that expansion hasn't yet materialized in revenue. The stock trades at 31.3x trailing earnings, a premium justified only if suzetrigine and pain programs deliver material revenue by late 2026. My 3-month target of $485 reflects sideways consolidation as the market waits for Q2 2026 earnings and early suzetrigine traction signals. My 6-month target of $520 assumes Morgan Stanley's $612 thesis holds partially true—one successful late-stage readout or launch guidance revision catalyzes multiple expansion. The key risk: if Q2 earnings disappoint or pipeline delays surface, the 31x multiple compresses to 26–27x peer median, driving the stock to $420–$440. At current levels, risk-reward favors patient holders, not new longs.
G Gemini	3M Target $525.00	6M Target $575.00	Reasoning My thesis is that Vertex will transition from a cystic fibrosis niche player to a broader specialty platform, driving a valuation re-rating as the market gains confidence in their non-opioid pipeline. The primary catalyst for my 6-month target is the commercial launch and initial script data for suzetrigine, which will prove the company can scale beyond its core franchise. Conversely, a failure to secure favorable reimbursement terms for this new drug would break my thesis and force a multiple contraction. We are currently paying a P/E ratio of 31.3. This means investors are paying over 31 dollars for every dollar of annual earnings, betting that future pipeline breakthroughs will justify this premium.
C Chatgpt	3M Target $612.00	6M Target $640.00	Reasoning My thesis is Vertex can trend higher if the pipeline proves durable and the balance sheet remains a fortress. Catalyst: a positive phase 3 readout for suzetrigine or stronger Q2 guidance would push the stock. Risk: a late-stage trial disappointment or slower CF pipeline expansion could trigger multiple compression. As of now, Vertex trades around 493.84; my 3-month target is 612.

Latest News Recent headlines mentioning this company

Vertiv Stock Near Highs: Momentum Builds on Strong AI Demand Yahoo Finance · 1 week, 5 days ago
Vertex tops profit estimates as sales of new cystic fibrosis drug surge Yahoo Finance · 2 weeks ago
Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA Yahoo Finance · 2 weeks, 2 days ago
Conestoga Capital Advisors Exited Vertex (VRTX) as the Valuation No Longer Reflects a Favorable Risk-Reward Yahoo Finance · 3 weeks, 1 day ago
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models Yahoo Finance · 1 month ago
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley Yahoo Finance · 1 month, 1 week ago
CGUS, VRTX, ADP, APD: Large Inflows Detected at ETF Nasdaq · 2 months ago
My Top 3 Drug Stocks for March 2026 Nasdaq · 2 months ago

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

VRTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

VRTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

Moving averages & overlays

Volume

Oscillators

Momentum & trend

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

VRTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Peer Comparison Key metrics vs sector peers

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

VRTX AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Round 2 — Responses & Rebuttals

Round 3 — Final Rebuttals

Price Forecasts

Latest News Recent headlines mentioning this company

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals